Literature DB >> 32004878

Plasma-lactate levels in simulated seizures - An observational study.

Asher Lou Isenberg1, Mikkel Engberg Jensen2, Mette Lindelof2.   

Abstract

PURPOSE: Differentiating between epileptic seizures, convulsive syncope or non-epileptic seizures is a common diagnostic challenge in the acute setting. Plasma-lactate levels have previously been proposed as a tool to aid in differentiating between epileptic and non-epileptic seizures, with lower levels of lactate suggesting a non-epileptic origin. The aim of this study was to investigate levels of lactate in non-epileptic seizures.
METHODS: Healthy subjects were asked to perform a simulated seizure lasting no more than 5 min. Venous blood samples were taken before and immediately after the simulated seizure and analyzed using an ABL90 FLEX yielding information about lactate, pH, pO2,pCO2, electrolytes and plasma glucose.
RESULTS: 8 people participated in the study: 6 men and 2 women aged 27-45. The average pre-simulation lactate was 1.1 mmol/L while the average pH was 7.39. The average post-simulation lactate was 10.2 mmol/L while the average pH was 7.25. This means an average increase in plasma-lactate of 9.1 mmol/L and an average drop of 0.15 in pH.
CONCLUSION: Our data indicate that high rises in lactate levels are not specific for an epileptic origin. Further study of lactate as a marker for epileptic seizures is warrented.
Copyright © 2020 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Epilepsy; Lactate; NES; PNES; Seizures; Transient loss of consciousness

Year:  2020        PMID: 32004878     DOI: 10.1016/j.seizure.2020.01.008

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  1 in total

1.  Prehospital lactate levels in blood as a seizure biomarker: A multi-center observational study.

Authors:  Carl Magnusson; Johan Herlitz; Robert Höglind; Pär Wennberg; Anna Edelvik Tranberg; Christer Axelsson; Johan Zelano
Journal:  Epilepsia       Date:  2021-01-08       Impact factor: 5.864

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.